The promise of recombinant interleukin-2.
Moldawer
N
N
Kidney Cancer Program, University of California, Los Angeles, USA.
Carr
E
E
D016907:Adverse Drug Reaction Reporting Systems; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000451:nursing; D010347:Patient Care Planning; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000009:adverse effects* / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins